Product image of Misbadi (Dabigatran Etexilate) supplied by GNH India

Misbadi

Active Ingredient:
Dabigatran Etexilate
Origin:
EU

Misbadi (Dabigatran Etexilate)

Dabigatran etexilate, the active ingredient in Misbadi, is a direct thrombin inhibitor presented as an oral tablet for oral use. It is used to reduce the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and to treat and prevent deep vein thrombosis and pulmonary embolism.

GNH India supplies Misbadi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Towa Pharmaceutical Europe S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Misbadi is a direct thrombin inhibitor indicated for several thrombo‑embolic conditions.

  • Non‑valvular atrial fibrillation: reduces the risk of stroke and systemic embolism.
  • Deep vein thrombosis (DVT): treats acute DVT and helps prevent recurrence.
  • Pulmonary embolism (PE): treats acute PE and helps prevent recurrence.

How It Works

  • Dabigatran etexilate is a reversible direct inhibitor of thrombin (factor IIa). After oral absorption, it is converted to dabigatran, which binds to the active site of thrombin, blocking the conversion of fibrinogen to fibrin and inhibiting platelet activation, thereby interrupting the final step of the coagulation cascade.

Side Effects

Common side effects are generally mild and related to the gastrointestinal tract.

Common Side Effects

  • Dyspepsia: upset stomach or indigestion.
  • Gastrointestinal bleeding: minor bleeding from the gut.
  • Nausea: feeling of sickness.
  • Abdominal pain: discomfort in the stomach area.
  • Diarrhea: loose stools.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Major bleeding: potentially life‑threatening hemorrhage.
  • Hemorrhagic stroke: bleeding within the brain.
  • Myocardial infarction: rare heart attack events.
  • Hepatic injury: liver function abnormalities.
  • Allergic reactions: including anaphylaxis.
  • Thrombocytopenia: low platelet count.

Precautions & Warnings

Before prescribing Misbadi, clinicians should evaluate several safety factors.

  • Renal function assessment: evaluate creatinine clearance prior to initiation.
  • Bleeding risk assessment: avoid in patients with active major bleeding.
  • Concomitant antiplatelet therapy: use caution when combined with aspirin or clopidogrel.
  • Surgery or invasive procedures: discontinue according to recommended timing before procedures.
  • Elderly patients: monitor closely for bleeding complications.
  • Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture.

Avoid Interactions

Misbadi may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong P‑gp inhibitors (e.g., ketoconazole, itraconazole): may increase dabigatran exposure.
  • Combined use with other anticoagulants (e.g., warfarin, heparin): heightened bleeding risk.
  • NSAIDs and antiplatelet agents: increased risk of gastrointestinal bleeding.

Moderate Interactions (Monitor Closely)

  • P‑gp inducers (e.g., rifampin, carbamazepine): may reduce dabigatran efficacy.
  • Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.
  • Certain antiviral agents (e.g., ritonavir): may alter plasma levels of dabigatran.

Frequently Asked Questions

Misbadi contains dabigatran etexilate and is prescribed to lower the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation, as well as to treat and prevent deep vein thrombosis and pulmonary embolism.

After oral intake, dabigatran etexilate is converted to dabigatran, which directly and reversibly binds to thrombin (factor IIa). This blocks the conversion of fibrinogen to fibrin and prevents platelet activation, thereby interrupting the final step of clot formation.

The appropriate dose of Misbadi is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, age, and other relevant factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for dabigatran etexilate in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Misbadi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Misbadi (dabigatran) is a direct oral anticoagulant (DOAC) that does not require routine coagulation monitoring, unlike warfarin, a vitamin K antagonist. Compared with other DOACs, dabigatran has a specific reversal agent (idarucizumab) and is primarily eliminated by the kidneys, making renal function a key consideration.

Misbadi tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Misbadi is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific timing instructions provided by their prescriber.

The most serious risks include major or life‑threatening bleeding, such as gastrointestinal hemorrhage, intracranial bleeding, and hemorrhagic stroke. Patients should seek immediate medical attention if they notice unusual bruising, blood in urine or stool, severe headache, or any signs of internal bleeding.

Misbadi is contraindicated in individuals with active major bleeding, severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to dabigatran or any excipients, and in patients with mechanical heart valves. Clinicians must assess each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dabigatran Etexilate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT